Ctrl K
Last 5 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|---|---|
| P/E Ratio → | -55.04 | — | — | 103.68 | — | — |
| — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| P/B Ratio | 37.13 | 316.58 | 15.42 | 24.75 | — | — |
| — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 99.45 | — | — |
| — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — |
| — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|---|---|
| ROE | -141.7% | -171.9% | -18.0% | 10.6% | -163.4% | -69.9% |
| — | -146.0% | — | — | — | — | |
| ROA | -45.0% | -32.9% | -6.3% | 3.4% | -43.9% | -28.6% |
| — | -14.7% | — | — | — | — | |
| ROIC | — | — | -313.3% | — | — | — |
| — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 8.91 | 0.98 | 0.02 | 0.16 | 0.06 |
| — | +15487.6% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — |
| — | — | — | — | — | — | |
| Current Ratio | 0.87 | 1.19 | 2.23 | 0.87 | 1.43 | 3.20 |
| — | -62.8% | — | — | — | — | |
| Quick Ratio | 0.87 | 1.19 | 2.23 | 0.87 | 1.43 | 3.20 |
| — | -62.8% | — | — | — | — | |
| Interest Coverage | — | -6.75 | — | — | — | — |
| — | — | — | — | — | — |
Includes 30+ ratios · 5 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TTRX stock.
Turn Therapeutics Inc.'s current P/E is -55.0x. The average P/E over the last 1 quarters is 103.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Turn Therapeutics Inc.'s business trajectory between earnings reports.